3T MRI-Compatible Small Body Array Gets FDA Nod
Featuring a lightweight body contouring design, the Small Body Array reportedly facilitates optimal signal-to-noise ratio (SNR) and between 10 and 40 percent faster throughput.
The Food and Drug Administration (FDA) has granted 510(k) clearance for a 3T magnetic resonance imaging (MRI)-compatible Small Body Array, which emphasizes a body contouring design and coils that are 80 percent lighter than conventional coils.
The body-hugging design of the Small Body Array adapts to a wide range of patient anatomies and sizes, according to InkSpace Imaging, the developer of the Small Body Array. The company emphasized that the Small Body Array provides optimal signal-to-noise ration (SNR), which improves detection of subtle abnormalities that may be missed by conventional coils.
In addition to increased patient comfort, InkSpace Imaging said the Small Body Array offers high coil element density, which helps streamline MRI acquisition. The company noted that the coils with the Small Body Array allow up to 40 percent faster throughput.
“The FDA clearance of InkSpace Imaging's Small Body Array marks a pivotal moment in MRI technology advancement. Our suite of MR coils is a game-changer, offering total freedom in coil positioning and handling,” noted Peter Fischer, the CEO of InkSpace Imaging. “What's truly impressive is how our thin flexible coil contours to each patient's body, offering comfort while enhancing image quality. It's a win-win for patients and health-care providers alike."
InkSpace Imaging said the Small Body Array is compatible with the Magnetom Skyra (Siemens Healthineers) and Magnetom Vida (Siemens Healthineers) series 3T MRI scanners.
Recent Videos
Related Content
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Article
Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025Article
The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Article
Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
